Skip to search formSkip to main contentSkip to account menu

PSI 6130

Known as: PSI-6130, PSI6130 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Over the last 15 years, an increase in knowledge of the structure, function, life cycle, and pathogenesis of hepatitis C virus… 
2017
2017
  • V. Roy
  • 2017
  • Corpus ID: 158620988
The Financialization of a Cure: A Political Economy of Biomedical Innovation, Pricing, and Public Health Victor Roy Sofosbuvir… 
2013
2013
hepatitis C virus (HCV) drug was approved by the US Food and Drug Administration on 6 December, the specialist antiviral company… 
2011
2011
Hepatitis C virus(HCV),is one of the major causes of cirrhosis,hepatocellular carcinoma.HCV infection affects 180 million people… 
2010
2010
Introduction. RG7128 (prodrug of PSI-6130) shows potent antiviral efficacy in patients infected with hepatitis C virus (HCV… 
2008
2008
Background: Hepatitis C virus (HCV) polymerase is an essential enzyme for HCV replication and has multiple inhibitor binding… 
2008
2008
beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a potent inhibitor of hepatitis C virus (HCV) RNA replication in an… 
2007
2007
ABSTRACT β-d-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) is an effective inhibitor of hepatitis C virus (HCV) replication…